SYMPATHETIC HYPERACTIVITY IN CHRONIC KIDNEY DISEASE PATIENTS: FROM PATHOGENESIS TO TREATMENT
Abstract
Sympathetic nervous system plays a crucial role in the development of cardiovascular complications in chronic kidney disease (CKD) patients. The aim of this review is to summarize up-to-date knowledge of the sympathetic hyperactivity in the pathogenesis of CKD, its clinical relevance, and as the options of current treatment.
Downloads
References
Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis / Kavi J. Littlewood, Wolfgang Greiner, Dominique Baum, [et al.] // [Електронний ресурс]: BMC Nephrol. – 2007. – V. 8. – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976090/.
All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan / C. P.Wen, T. Y. D. Cheng, M. K. Tsai [et al.] // The Lancet. – 2008. – V. 371. – № 9631. – P. 2173–2182.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis / Mahmoodi B. K., Matsushita K., Woodward M., [et al.] // Lancet. – 2012. – V. 380. – P. 1649-1661.
Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. / K. Masuo, H. Rakugi, T. Ogihara, M. D. Esler, G. W. Lambert // Current Diabetes Reviews. – 2010. – V. 6. – № 2. – P. 58-67.
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors / Shlipak M. G., Fried L. F., Cushman M., [et al.] // JAMA. – 2005. – V. 293. – P. 1737-1745.
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women / M. K. Pöyhönen-Alho, K. Manhem, [et al.] // Journal of Hypertension. – 2008. – V. 26. – №12. – Р. 2445-2449.
Chazova I. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study / Irina Chazova, Markus P. Schlaich // [Електронний ресурс]: International Journal of Hypertension. – 2013. – V. 2013. – Режим доступу: http://www.hindawi.com/journals/ijht/2013/541689/
Desir G. V. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease / Desir G. V. // Curr. Opin. Nephrol. Hypertens. – 2008. – V. 17. – Р. 181-185.
Device-Based Antihypertensive Therapy. Therapeutic Modulation of the Autonomic Nervous System / H. Krum, P. Sobotka, M. Bo¨hm, M. Esler, [et al.] // Circulation. – 2011. – V. 123. – Р. 209-215.
Early sympathetic activation in the initial clinical stages of chronic renal failure / Grassi G., Quarti-Trevano F., Seravalle G., [et al.] // Hypertension. – 2011. – V. 57. – P. 846-851.
Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats / K. Amann, L. Christian Rump, A. Simonaviciene, [et al.] // JASN. – 2000. – V. 11. – № 8. – Р. 1469- 1478.
Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease / Hausberg M., Tokmak F., Pavenstädt H., [et al.] // J. Hypertens. – 2010. – V. 28(9). – P. 1920-1927.
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? / P. Stenvinkel, J. J. Carrero, [et al.] // Clinical Journal of the American Society of Nephrology. – 2008. – V. 3. – № 2. – Р. 505-521.
ESH position paper: renal denervation - an interventional therapy of resistant hypertension / Schmieder R. E., Redon J., Grassi G., Kjeldsen S. E., [et al.] // J Hypertens. – 2012. – V. 30(5). – Р. 837-841.
Eva E. Vink. Sympathetic Hyperactivity in Chronic Kidney Disease: Pathophysiology and (New) Treatment Options / Eva E. Vink, Rosa L. de Jager, Peter J. Blankestijn // Current Hypertension Reports. – 2013. – V. 15. – № 2. – Р. 95-101.
Fisher J. P. Central sympathetic overactivity: maladies and mechanisms / J. P. Fisher, C. N. Young, and P. J. Fadel // Autonomic Neuroscience. – 2009. – V. 148. – № 1-2. – Р. 5-15.
Jeanie Park. Cardiovascular Risk in Chronic Kidney Disease: Role of the Sympathetic Nervous System / Jeanie Park // [Електронний ресурс] : Cardiology Research and Practice. – V. 2012. – Режим доступу: http://www.hindawi.com/journals/crp/2012/319432/
Joyner M. J. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications / Joyner M. J., Charkoudian N., Wallin B. G. // Hypertension. – 2010. – V. 56. – Р. 10-6.
Low glomerular filtration rate and risk of stroke: meta-analysis / Lee M., Saver J. L., Chang K. H., Liao H. W., [et al.] // [Електронний ресурс] : BMJ. – 2010. – V. 30 – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948650/
Major pathways of the reno–cardiovascular link: the sympathetic and renin– angiotensin systems / P. J. Blankestijn, G. London, D. Fliser, K. J. Jager, [et al.] // Kidney International Supplements. – 2011. – V. 1(1). – Р. 13-16.
Markus P. Schlaich. Sympathetic Activation in Chronic Kidney Disease : Out of the Shadow / Markus P. Schlaich // Hypertension. – 2011. – V. 57. – P. 683- 685.
Matsushita K. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis / K. Matsushita, M. van der Velde, B. C. Astor, [et al.] // The Lancet. – 2010. – V. 375. – № 9731. – Р. 2073-2081.
Mechanisms of autonomic nervous system dysfunction in uremia / Campese V. M., Romoff M. S., Levitan D., [et al.] // Kidney Int. – 1981. – V. 20. – Р. 246- 253.
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial / G. Derosa, A. F. G. Cicero, A. D'Angelo [et al.] // Clinical Therapeutics. – 2007 – V. 29. – № 4. – Р. 602– 610.
Minushkina L. O. Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes / Minushkina L. O. // Kardiologiia. – 2011. – V. 51(4). – Р. 74-78.
Modulation of peripheral chemoreflex by neurohumoral adaptations after kidney transplantation / Rassaf T., Westenfeld R., Balzer J., [et al.] // Eur. J. Med. – 2010. – 15. – Suppl. 2. – Р. 83-87.
Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt / H. Aceros, G. Farah, L. Cobos- Puc, [et al.] // Br. J. Pharmacol. – 2011. – V. 164(3). – Р. 946-957.
Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan- treated chronic renal failure / Neumann J., Ligtenberg G., Oey L., [et al.] // J. Am. Soc. Nephrol. – 2004. – V. 11. – Р. 2902-2907.
Moxonidine prevents ischemia/reperfusion-induced renal injury in rats / Tsutsui H., Sugiura T., Hayashi K., [et al.] // Eur. J. Pharmacol. – 2009. – V. 28; 603(1-3). – P. 73-78.
Murray Esler. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management / Murray Esler // Journal of Applied Physiology – 2010. – V. 108. – № 2. – Р. 227-237.
Murray Esler. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension / Murray Esler // Experimental Physiology – 2011 – V. 96. – Р. 611-622.
Parati G. The human sympathetic nervous system: its relevance in hypertension and heart failure / Gianfranco Parati, Murray Esler // European Heart Journal. – 2012. – V. 33. – Р. 1058-1066.
Peter J. Blankestijn. Sympathetic hyperactivity in chronic kidney disease / Peter J. Blankestijn // Nephrol. Dial. Transplant. – 2004 – V. 19. – Р. 1354- 1357.
Pharmacological properties of the central antihypertensive agent, moxonidine / Edwards L. P., Brown-Bryan T. A., McLean L., Ernsberger P. // Cardiovasc Ther. – 2012. – V. 30(4). – P. 199-208.
Plasma levels of norepinephrine and dopamine-β-hydroxylase in CRF patients treated with dialysis / Lake C. R., Ziegler M. G., Coleman M. D., Kopin I.J. // Cardiovasc. Med. – 1979. – V. 4. – Р. 1099-1111.
Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research / Ott C., Schmid A., Ditting T., Sobotka P. A. // J. Clin. Hypertens. – 2012. – V. 14(11). – P. 799-801.
Renal Denervation Ultima Ratio or Standard in Treatment-Resistant Hypertension / A. Persu, J. Renkin, L. Thijs, . J. A. Staessen // Hypertension. – 2012. – V. 60(3). – Р. 596-606.
Renalase's Expression and Distribution in Renal Tissue and Cells / F. Wang, T. Xing, J. Li, [et al.] // [Електронний ресурс] : PLoS One. – 2012. – V. 7(10) – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463591/#pone.0046442-Xu1
Ritz E. Control of sympathetic activity – new insights; new therapeutic targets? / Ritz E., Rump L. C. // Nephrol. Dial. Transplant. – 2010. – №: 10. – Р. 1048- 1050.
Rucker D. Cardiovascular risk and management in chronic kidney disease / D. Rucker, M. Tonelli // Nature Reviews Nephrology. – 2009. – V. 5. – № 5. – Р. 287-296.
Simon C. Malpas. Sympathetic Nervous System Overactivity and Its Role in the Development of Cardiovascular Disease / Simon C. Malpas // Physiol Rev. – 2010. – V. 9. – №. 2. – Р. 513-557.
Sudden cardiac death in hemodialysis patients: an in-depth review / D. Green, P. R. Roberts, D. I. New, and P. A. Kalra // American Journal of Kidney Diseases. – 2011. – V. 57. – № 6. – Р. 921-929.
Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment / Laima Siddiqi, Niek H. Prakken, Birgitta K. Velthuis, [et al.] // Nephrol. Dial. Transplant. – 2010. – V. – 2. (10). – P. 3272-3277.
Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension / Klein I. H., Ligtenberg G., Oey P. L., [et al.] // J. Am. Soc Nephrol. – 2001– № 24. – Р. 27-2433.
Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment / Penne E. L., Neumann J., Klein I. H., [et al.] J. Nephrol. – 2009. – V. 22. – P. 208-215.
Sympathetic nervous activation in obesity and the metabolic syndrome – causes, consequences and therapeutic implications / G. W. Lambert, N. E. Straznicky, E. A. Lambert, J. B. Dixon, M. P. Schlaich // Pharmacology and Therapeutics. – 2010. – V. 126, – № 2. – P. 159-172.
Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults / E. Lambert, C. I. Sari, T. Dawood, [et al.] // Hypertension. – 2010. – V. 56. – № 3. – P. 351-358.
Sympathetic overactivity in patients with chronic renal failure / Converse R. L., Jacobsen T. N., Toto R. D., Jost C. M., [et al.] // N. Engl. J. Med. – 1992. – V. 327. – P. 1912-1918.
Sympatho-renal axis in chronic disease / Paul A. Sobotka, Felix Mahfoud, Markus P. Schlaich, [et al] // Clin Res Cardiol. – 2011. – V. 100. – P. 1049- 1057.
The role of sympathetic nervous activity in renal injury and end-stage renal disease / Masuo K., Lambert G. W., Esler M. D., Rakugi H. // Hypertens Res. – 2010. – V. 33(6). – P. 521-528.
Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? / Ditting T., Freisinger W., Siegel K., [et al.] // Hypertension. – 2012. – V. 59. – P. 467-476.
Volders P. G. A. Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis / Volders P. G. A. // Heart Rhythm. – 2010. – V. 71. – № 2. – Р. 1900-1906.
Yaduvanshi A. CRT-128 Renal Artery Denervation in Chronic Kidney Disease Patients / A. Yaduvanshi, M. Nair // J. Am. Coll. Cardiol. Intv. – 2013. – V. 6 (2_S). – Р. S41-S42.
